Caricamento...
Tubulosine selectively inhibits JAK3 signalling by binding to the ATP‐binding site of the kinase of JAK3
Gain‐ or loss‐of‐function mutations in Janus kinase 3 (JAK3) contribute to the pathogenesis of various haematopoietic malignancies and immune disorders, suggesting that aberrant JAK3 signalling is an attractive therapeutic target to treat these disorders. In this study, we performed structure‐based...
Salvato in:
| Pubblicato in: | J Cell Mol Med |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7339168/ https://ncbi.nlm.nih.gov/pubmed/32558259 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.15362 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|